Amylyx Pharmaceuticals is a clinical stage biotechnology company. Co. is developing therapies for amyotrophic lateral sclerosis (ALS) and a range of other neurodegenerative diseases, including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, multiple sclerosis, Friedreich's ataxia, and Leigh's syndrome. Co. is pursuing commercialization of AMX0035, which is a drug candidate for patients with ALS. AMX0035 is a dual unfolded protein response-Bcl-2 Associated X-protein apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. The AMLX YTD return is shown above.
The YTD Return on the AMLX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AMLX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMLX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|